FACSAria II Cell Sorter

FACSAria II 细胞分选仪

基本信息

  • 批准号:
    8052972
  • 负责人:
  • 金额:
    $ 51.41万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-03-07 至 2012-03-06
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): In order to address the overwhelming demand for multi-color flow cytometry cell sorting, LIAI is requesting funds for the replacement of a Becton Dickinson (BD; BD Biosciences San Jose, CA) FACS Vantage SE that the manufacturer will no longer support, with a 9-color and 2 scatter parameter digital BD FACSAria II cell sorter. The facility already operates at near maximum capacity due to incredible demand from an institute devoted to the study of the immune system, and only by replacement of this instrument with a faster and more capable unit will the facility be able to fully support the research program. The requested instrument has been chosen because it can analyze up to 11 parameters simultaneously and will significantly enhance the ability to evaluate numerous phenotypic parameters of a cell concurrently, as well as greatly increased sample throughput/efficiency over the current instrument. Importantly, this high- speed instrument will maximize the opportunity to sort from high cell count samples and capture rare cell populations that are often technically challenging to collect. With a large group of extraordinarily high volume users, replacement of the current instrument will also leverage the ability to fully segregate conventional samples from biohazardous samples that will be run on an existing unit in a purpose built room and hood combination. This segregation will greatly increase safety and scheduling efficiencies that in total are expected to increase the facilities sorting capacity by nearly 1,000 hours per year; an urgent need in the support of over 100 NIH-supported investigators.
描述(由申请人提供):为了满足对多色流式细胞术细胞分选的巨大需求,LIAI正在申请资金,以替换制造商将不再支持的Becton Dickinson (BD; BD Biosciences San Jose, CA) FACS Vantage SE,使用9色和2散射参数的数字BD FACSAria II细胞分选仪。由于一个致力于免疫系统研究的研究所的惊人需求,该设施已经在接近最大容量的情况下运行,只有用更快、更有能力的设备替换这台仪器,该设施才能完全支持研究计划。之所以选择所要求的仪器,是因为它可以同时分析多达11个参数,并将显著增强同时评估细胞众多表型参数的能力,以及比现有仪器大大提高样品吞吐量/效率。重要的是,这种高速仪器将最大限度地提高从高细胞计数样品中分选的机会,并捕获通常在技术上具有挑战性的罕见细胞群。对于大量的高容量用户,更换现有仪器还将充分利用将常规样品与生物危险样品完全分离的能力,这些样品将在专门建造的房间和通风柜组合的现有装置上运行。这种隔离将大大提高安全性和调度效率,预计每年将使该设施的分拣能力增加近1000小时;迫切需要100多名nih支持的调查人员的支持。

项目成果

期刊论文数量(21)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Transcriptional Profiling of Th2 Cells Identifies Pathogenic Features Associated with Asthma.
  • DOI:
    10.4049/jimmunol.1600397
  • 发表时间:
    2016-07-15
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Seumois G;Zapardiel-Gonzalo J;White B;Singh D;Schulten V;Dillon M;Hinz D;Broide DH;Sette A;Peters B;Vijayanand P
  • 通讯作者:
    Vijayanand P
E3 Ligase VHL Promotes Group 2 Innate Lymphoid Cell Maturation and Function via Glycolysis Inhibition and Induction of Interleukin-33 Receptor.
  • DOI:
    10.1016/j.immuni.2017.12.013
  • 发表时间:
    2018-02-20
  • 期刊:
  • 影响因子:
    32.4
  • 作者:
    Li Q;Li D;Zhang X;Wan Q;Zhang W;Zheng M;Zou L;Elly C;Lee JH;Liu YC
  • 通讯作者:
    Liu YC
Transcriptional profile of tuberculosis antigen-specific T cells reveals novel multifunctional features.
  • DOI:
    10.4049/jimmunol.1401151
  • 发表时间:
    2014-09-15
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Arlehamn CL;Seumois G;Gerasimova A;Huang C;Fu Z;Yue X;Sette A;Vijayanand P;Peters B
  • 通讯作者:
    Peters B
Hypoxia induces adrenomedullin from lung epithelia, stimulating ILC2 inflammation and immunity.
Inducible disruption of Tet genes results in myeloid malignancy, readthrough transcription, and a heterochromatin-to-euchromatin switch.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael Croft其他文献

Michael Croft的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael Croft', 18)}}的其他基金

TWEAK and Skin Inflammation
调整和皮肤炎症
  • 批准号:
    10400699
  • 财政年份:
    2018
  • 资助金额:
    $ 51.41万
  • 项目类别:
A Treg cell-intrinsic CTLA4-PKC-eta signaling pathway mediating contact-dependent suppression of tumor immunity: A novel target for cancer immunotherapy
Treg 细胞固有的 CTLA4-PKC-eta 信号通路介导接触依赖性肿瘤免疫抑制:癌症免疫治疗的新靶点
  • 批准号:
    10531229
  • 财政年份:
    2018
  • 资助金额:
    $ 51.41万
  • 项目类别:
Immune Regulation by Deubiquitination
通过去泛素化进行免疫调节
  • 批准号:
    9982199
  • 财政年份:
    2018
  • 资助金额:
    $ 51.41万
  • 项目类别:
A Treg cell-intrinsic CTLA4-PKC-eta signaling pathway mediating contact-dependent suppression of tumor immunity: A novel target for cancer immunotherapy
Treg 细胞固有的 CTLA4-PKC-eta 信号通路介导接触依赖性肿瘤免疫抑制:癌症免疫治疗的新靶点
  • 批准号:
    10053328
  • 财政年份:
    2018
  • 资助金额:
    $ 51.41万
  • 项目类别:
TWEAK and Skin Inflammation
调整和皮肤炎症
  • 批准号:
    9910059
  • 财政年份:
    2018
  • 资助金额:
    $ 51.41万
  • 项目类别:
A Treg cell-intrinsic CTLA4-PKC-eta signaling pathway mediating contact-dependent suppression of tumor immunity: A novel target for cancer immunotherapy
Treg 细胞固有的 CTLA4-PKC-eta 信号通路介导接触依赖性肿瘤免疫抑制:癌症免疫治疗的新靶点
  • 批准号:
    10310411
  • 财政年份:
    2018
  • 资助金额:
    $ 51.41万
  • 项目类别:
TWEAK and Skin Inflammation
调整和皮肤炎症
  • 批准号:
    10152528
  • 财政年份:
    2018
  • 资助金额:
    $ 51.41万
  • 项目类别:
Immune Regulation by Deubiquitination
通过去泛素化进行免疫调节
  • 批准号:
    9788250
  • 财政年份:
    2018
  • 资助金额:
    $ 51.41万
  • 项目类别:
Training in Immunological Mechanisms
免疫机制培训
  • 批准号:
    9321444
  • 财政年份:
    2016
  • 资助金额:
    $ 51.41万
  • 项目类别:
Training in Immunological Mechanisms
免疫机制培训
  • 批准号:
    10675443
  • 财政年份:
    2016
  • 资助金额:
    $ 51.41万
  • 项目类别:

相似海外基金

Determination of the optimum peak cell count for each yeast strain.
确定每种酵母菌株的最佳峰值细胞计数。
  • 批准号:
    494444-2016
  • 财政年份:
    2016
  • 资助金额:
    $ 51.41万
  • 项目类别:
    Experience Awards (previously Industrial Undergraduate Student Research Awards)
Point-of-care blood cell count through micro-ELISA
通过微量 ELISA 进行即时血细胞计数
  • 批准号:
    131948
  • 财政年份:
    2015
  • 资助金额:
    $ 51.41万
  • 项目类别:
    Feasibility Studies
THE COMPARISON OF PLACENTAL AND UMBILICAL NUCLEATED RED BLOOD CELL COUNT
胎盘和脐带有核红细胞计数的比较
  • 批准号:
    7376109
  • 财政年份:
    2005
  • 资助金额:
    $ 51.41万
  • 项目类别:
THE COMPARISON OF PLACENTAL AND UMBILICAL NUCLEATED RED BLOOD CELL COUNT
胎盘和脐带有核红细胞计数的比较
  • 批准号:
    7206410
  • 财政年份:
    2004
  • 资助金额:
    $ 51.41万
  • 项目类别:
A Simple Point of Care White Blood Cell Count Test
简单的护理点白细胞计数测试
  • 批准号:
    6830358
  • 财政年份:
    2001
  • 资助金额:
    $ 51.41万
  • 项目类别:
A Simple Point of Care White Blood Cell Count Test
简单的护理点白细胞计数测试
  • 批准号:
    6943868
  • 财政年份:
    2001
  • 资助金额:
    $ 51.41万
  • 项目类别:
A Simple Point Of Care White Blood Cell Count Test
简单的护理点白细胞计数测试
  • 批准号:
    6403018
  • 财政年份:
    2001
  • 资助金额:
    $ 51.41万
  • 项目类别:
NEONATAL WHITE BLOOD CELL COUNT IN PREMATURE INFANTS
早产儿新生儿白细胞计数
  • 批准号:
    3926574
  • 财政年份:
  • 资助金额:
    $ 51.41万
  • 项目类别:
NEONATAL WHITE BLOOD CELL COUNT IN PREMATURE INFANTS
早产儿新生儿白细胞计数
  • 批准号:
    3885899
  • 财政年份:
  • 资助金额:
    $ 51.41万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了